■Abstract #LBA10

CALGB/SWOG 80405試験：治療戦略の一環として手術を受けた患者の解析

CALGB/SWOG 80405: Patients Undergoing Surgery as Part of Treatment Strategy

A. Venook, et al.

■Abstract #LBA11

FIRE-3試験の最終的RAS 評価可能集団における客観的奏効、早期腫瘍縮小、奏効の深さの独立画像評価

Independent Radiological Evaluation of Objective Response, Early Tumor Shrinkage, and Depth of Response in FIRE-3 (AIO KRK-0306) in the Final RAS Evaluable Population

S. Stintzing, et al.

■Abstract #LBA13

標準治療に抵抗性となった切除不能進行・再発大腸癌患者に対するTAS-102のプラセボ対照第III相試験：RECOURSE試験

Phase III RECOURSE Trial of TAS-102 vs. Placebo, with Best Supportive Care (BSC), in Patients (pts) with Metastatic Colorectal Cancer (mCRC) Refractory to Standard Therapies

E. Van Cutsem, et al.

■Abstract #LBA15

進行胃癌に対するPembrolizumabの第Ib相試験

A Phase 1b Study of Pembrolizumab (Pembro; MK-3475) in Patients with Advanced Gastric Cancer

K. Muro, et al.

■Abstract #LBA16

1st-lineにおいてSorafenibを投与した進行肝細胞癌に対する2nd-lineとしてのRamucirumab：無作為化第III相試験 (REACH試験)

Ramucirumab as Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-line Therapy with Sorafenib: Results from the Randomized Phase III REACH Study

A. Zhu, et al.

■Abstract #LBA17

抗血管新生療法歴のある肝細胞癌患者に対するAxitinib + BSCとプラセボ + BSCの無作為化試験

Randomised Study of Axitinib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Hepatocellular Carcinoma Following Prior Antiangiogenic Therapy

Y. Kang, et al.

■Abstract #LBA18

CONKO-006試験：膵癌のR1切除患者に対するGemcitabine + Sorafenib/プラセボによる術後補助化学療法の無作為化二重盲検第IIb相試験

CONKO-006: A Randomized Double-blinded Phase IIb-Study of Adjuvant Therapy with Gemcitabine + Sorafenib / Placebo for Patients with R1-Resection of Pancreatic Cancer

M. Sinn, et al.

■Abstract #499O

KRAS 野生型の切除不能進行・再発大腸癌に対する1st-lineにおけるmFOLFOX6 + Cetuximab (8サイクル) 後の維持療法としてのmFOLFOX6 + Cetuximab vs. Cetuximab単剤の第II相試験：MACRO-2試験

Phase II Study of First-line mFOLFOX plus Cetuximab (C) for 8 Cycles Followed by mFOLFOX plus C or Single Agent (s/a) C as Maintenance Therapy in Patients (p) with KRAS Wild Type Metastatic Colorectal Cancer (mCRC): the MACRO-2 Trial

P. Garcia Alfonso, et al.

■Abstract #501O

CALGB/SWOG 80405試験：未治療の切除不能進行・再発大腸腺癌患者に対するFOLFIRI / mFOLFOX6とBevacizumabまたはCetuximab併用の第III相試験−拡大RAS 解析

CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (Pts) with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (MCRC): Expanded RAS analyses

H. Lenz, et al.

■Abstract #LBA19

進行再発膵癌患者に対する1st-lineとしてのOncolytic virus、Reolysinの多施設共同第II相試験：最終解析

A Multi-institutional Randomized Phase 2 Trial of the Oncolytic Virus Reolysin in the First Line Treatment Metastatic Adenocarcinoma of the Pancreas (MAP): Final Analysis

T. Bekaii-Saab, et al.

■Abstract #508PD

FIRE-3試験におけるFOLFIRI + CetuximabまたはFOLFIRI + Bevacizumabによる1st-line後の2nd-lineの解析

Second-line Therapies in Patients with KRAS Wild-type Metastatic Colorectal Cancer (mCRC) after First-line Therapy with FOLFIRI in Combination with Cetuximab or Bevacizumab in the AIO KRK0306 (FIRE-3) Trial

D. P. Modest, et al.

■Abstract #209P

大腸癌における全RAS 変異解析用新規マルチプレックス検査キットの臨床的検証：多施設共同前向き試験、RASKET試験の結果

Clinical Validation of a Novel Multiplex Kit for all RAS Mutations in Colorectal Cancer: Results of RASKET (RAS KEy Testing) Prospective Multicenter Study

K. Yamaguchi, et al.

■Abstract #515P

RAS およびBRAF 野生型切除不能進行・再発大腸癌患者に対するFOLFOXIRI + Bevacizumab vs. FOLFOXIRI + 抗EGFR抗体薬：抗腫瘍効果の解析

FOLFOXIRI plus Bevacizumab (BV) or plus Anti-EGFR Antibodies in RAS and BRAF Wild-type (wt) Metastatic Colorectal Cancer (mCRC) Patients (pts): Analysis of Tumor Response

L. Salvatore, et al.

■Abstract #546P

2nd-lineとしてのFOLFIRI + Panitumumab vs. FOLFIRIにおける腫瘍縮小と奏効によるアウトカム

Tumour Shrinkage and Response Outcomes during Second-line Panitumumab + FOLFIRI vs. FOLFIRI Treatment

M. Peeters, et al.

■Abstract #547P　New

FOLFOX4 ± Panitumumabによる1st-lineにおいてベースライン時の年齢が有効性と安全性に及ぼす影響

Impact of Baseline Age on Efficacy and Safety of First-line Panitumumab + FOLFOX4 vs. FOLFOX4 Treatment

J. Douillard, et al.

■Abstract #548P

2nd-lineにおけるFOLFIRI + Panitumumab vs. FOLFIRI の有効性に対するベースライン因子および前治療の影響

Impact of Baseline Covariates and Prior Therapy on the Efficacy of Second-line Panitumumab + FOLFIRI vs. FOLFIRI Treatment

M. Peeters, et al.

■Abstract #549P

切除不能進行・再発大腸癌患者に対する1st-lineとしてのFOLFIRI + PanitumumabにおけるRAS /BRAF statusが有効性に及ぼす影響

Impact of Tumour RAS /BRAF Status on Efficacy of First-line Panitumumab + FOLFIRI in Patients with Metastatic Colorectal Cancer

M. Karthaus, et al.

■Abstract #551P

PLANET試験におけるRAS 解析：肝限局転移を有するKRAS 野生型大腸癌患者に対するFOLFOX4またはFOLFIRI + Panitumumabの第II相試験

RAS Analysis of the PLANET Study: Phase II Trial of Panitumumab (Pmab) plus FOLFOX4 or FOLFIRI in Subjects with Wild-type (WT) KRAS Colorectal Cancer (CRC) and Liver-limited Disease (LLD)

A. Abad, et al.